You mean your doctors and hospitals have completely failed at providing you recreational drugs for years for your stroke recovery? How fucking incompetent are they?
DMT (8 posts to November 2020)
ecstasy (19 posts to November 2012)
LSD (5 posts to September 2018)
magic mushrooms (10 posts to October 2014)
psilocybin (14 posts to May 2014)
Algernon Pharmaceuticals completes final dosing in DMT study for stroke and TBI treatment
News
AGN Neuro plans to publish the data from the study in an upcoming issue of a peer-reviewed paper
Algernon Pharmaceuticals Inc.’s (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) subsidiary Algernon Neuroscience will be the first company to test intravenous (IV) DMT on people suffering from traumatic brain injury or stroke.
On Monday, the clinical-stage pharmaceutical development company announced the successful completion of dosing in the final cohort of its Phase 1 clinical study involving AP-188 which is DMT.
AGN Neuro is the first company to test DMT at single escalating concentrations with an IV dose for a 6-hour duration. The safety review committee has confirmed no safety or tolerability issues with the highest dose.
This dose maintained plasma DMT concentrations at targeted levels and was below the established psychedelic dose.
The psychedelic dose of DMT was previously identified as 0.2 mg/kg by Dr. Rick Strassman, a DMT researcher and Algernon consultant, in his pioneering DMT human studies in the early 1990s.
DMT is believed to activate pathways involved in forming neuronal connections and has been shown to increase the number of dendritic spines on cortical neurons(Sounds very useful for stroke recovery). These spines form synapses with other neurons and are a critical site for neuronal transmission.
The Phase 1 trial was conducted at the Centre for Human Drug Research in Leiden, Netherlands. It aimed to identify the safety, tolerability and pharmacokinetics of sub-psychedelic doses of DMT when administered as an intravenous bolus followed by a prolonged infusion of 6 hours.
AGN Neuro plans to publish the data from the study in an upcoming issue of a peer-reviewed paper.
“Neuroplasticity’s role in healing the brain after an injury is one of the most exciting areas of research globally in the pursuit of a treatment for stroke and TBI, and AGN Neuro is at the forefront of this work,” Algernon CEO Christopher J. Moreau said.
Read more: Algernon partners with Yale University for phase II DMT study
Read more: Small Pharma gets approval for upcoming injectable DMT trial on humans
No comments:
Post a Comment